139 related articles for article (PubMed ID: 38330100)
21. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
Cancer Metab; 2017; 5():6. PubMed ID: 28852500
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.
Pelicano H; Zhang W; Liu J; Hammoudi N; Dai J; Xu RH; Pusztai L; Huang P
Breast Cancer Res; 2014 Sep; 16(5):434. PubMed ID: 25209360
[TBL] [Abstract][Full Text] [Related]
23. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
[TBL] [Abstract][Full Text] [Related]
24. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.
Chien YC; Liu LC; Ye HY; Wu JY; Yu YL
Am J Cancer Res; 2018; 8(3):422-434. PubMed ID: 29636998
[TBL] [Abstract][Full Text] [Related]
25. Hedgehog pathway orchestrates the interplay of histone modifications and tailors combination epigenetic therapies in breast cancer.
Wang X; Xu J; Sun Y; Cao S; Zeng H; Jin N; Shou M; Tang S; Chen Y; Huang M
Acta Pharm Sin B; 2023 Jun; 13(6):2601-2612. PubMed ID: 37425067
[TBL] [Abstract][Full Text] [Related]
26. Functional relationship of SNP (Ala490Thr) of an epigenetic gene
Gautam N; Verma H; Choudhary S; Kaur S; Silakari O
J Genet; 2021; 100():. PubMed ID: 34825659
[No Abstract] [Full Text] [Related]
27. Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer.
Gao B; Liu X; Li Z; Zhao L; Pan Y
Front Oncol; 2020; 10():600514. PubMed ID: 33665162
[TBL] [Abstract][Full Text] [Related]
28. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
29. Pyruvate kinase M2: regulatory circuits and potential for therapeutic intervention.
Gupta V; Wellen KE; Mazurek S; Bamezai RN
Curr Pharm Des; 2014; 20(15):2595-606. PubMed ID: 23859618
[TBL] [Abstract][Full Text] [Related]
30. PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis.
Liu F; Ma F; Wang Y; Hao L; Zeng H; Jia C; Wang Y; Liu P; Ong IM; Li B; Chen G; Jiang J; Gong S; Li L; Xu W
Nat Cell Biol; 2017 Nov; 19(11):1358-1370. PubMed ID: 29058718
[TBL] [Abstract][Full Text] [Related]
31. Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth.
Chiavarina B; Whitaker-Menezes D; Martinez-Outschoorn UE; Witkiewicz AK; Birbe R; Howell A; Pestell RG; Smith J; Daniel R; Sotgia F; Lisanti MP
Cancer Biol Ther; 2011 Dec; 12(12):1101-13. PubMed ID: 22236875
[TBL] [Abstract][Full Text] [Related]
32. Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.
Cohen AL; Piccolo SR; Cheng L; Soldi R; Han B; Johnson WE; Bild AH
BMC Med Genomics; 2013 Sep; 6():35. PubMed ID: 24079712
[TBL] [Abstract][Full Text] [Related]
33. RGCC-mediated PLK1 activity drives breast cancer lung metastasis by phosphorylating AMPKα2 to activate oxidative phosphorylation and fatty acid oxidation.
Cheng S; Wan X; Yang L; Qin Y; Chen S; Liu Y; Sun Y; Qiu Y; Huang L; Qin Q; Cui X; Wu M; Liu M
J Exp Clin Cancer Res; 2023 Dec; 42(1):342. PubMed ID: 38102722
[TBL] [Abstract][Full Text] [Related]
34. The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma.
Xiaoyu H; Yiru Y; Shuisheng S; Keyan C; Zixing Y; Shanglin C; Yuan W; Dongming C; Wangliang Z; Xudong B; Jie M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818780063. PubMed ID: 29916308
[TBL] [Abstract][Full Text] [Related]
35. Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.
Anwar T; Gonzalez ME; Kleer CG
Am J Pathol; 2021 May; 191(5):774-783. PubMed ID: 33556366
[TBL] [Abstract][Full Text] [Related]
36. The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.
Puckett DL; Alquraishi M; Chowanadisai W; Bettaieb A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503959
[TBL] [Abstract][Full Text] [Related]
37. EZH2 promotes a bi-lineage identity in basal-like breast cancer cells.
Granit RZ; Gabai Y; Hadar T; Karamansha Y; Liberman L; Waldhorn I; Gat-Viks I; Regev A; Maly B; Darash-Yahana M; Peretz T; Ben-Porath I
Oncogene; 2013 Aug; 32(33):3886-95. PubMed ID: 22986524
[TBL] [Abstract][Full Text] [Related]
38. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.
Chen NM; Neesse A; Dyck ML; Steuber B; Koenig AO; Lubeseder-Martellato C; Winter T; Forster T; Bohnenberger H; Kitz J; Reuter-Jessen K; Griesmann H; Gaedcke J; Grade M; Zhang JS; Tsai WC; Siveke J; Schildhaus HU; Ströbel P; Johnsen SA; Ellenrieder V; Hessmann E
Gastroenterology; 2017 May; 152(6):1507-1520.e15. PubMed ID: 28188746
[TBL] [Abstract][Full Text] [Related]
39. Enhancer of zeste homolog 2 (
Dudakovic A; Camilleri ET; Paradise CR; Samsonraj RM; Gluscevic M; Paggi CA; Begun DL; Khani F; Pichurin O; Ahmed FS; Elsayed R; Elsalanty M; McGee-Lawrence ME; Karperien M; Riester SM; Thaler R; Westendorf JJ; van Wijnen AJ
J Biol Chem; 2018 Aug; 293(33):12894-12907. PubMed ID: 29899112
[TBL] [Abstract][Full Text] [Related]
40. Cancer metabolism control by natural products: Pyruvate kinase M2 targeting therapeutics.
El-Far AH; Al Jaouni SK; Li X; Fu J
Phytother Res; 2022 Aug; 36(8):3181-3201. PubMed ID: 35794729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
